AgeX Therapeutics Profit Margin

The latest profit margin for AGE is -165.83% as of March 2026. That compares with 639.57% in the prior-year period — down 125.9% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside AgeX Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGE's profit margin moved from 639.57% to -165.83% — a 125.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AgeX Therapeutics's valuation or profitability profile.

Against Healthcare companies, AGE currently prints -165.83% for profit margin, while the sector average sits near 15.58%. That is roughly 106510.7% below the sector mean. Large gaps often invite a closer look at AgeX Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively AgeX Therapeutics converts resources into returns. At -165.83%, AGE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 639.57% in the prior-year period — down 125.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AGE's profit margin (-165.83%), review year-over-year change from 639.57%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.